This interactive, case-based OncoBlast activity helps clinicians navigate treatment decisions in NSCLC using molecular testing, targeted therapies, and immunotherapy. Through ABIM-style questions and expert explanations, learners will explore optimal diagnostic and treatment approaches based on actionable biomarkers.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 1/1/2025 | 12/31/2025 |
Faculty
Lei Deng (MD, University of Washington, Fred Hutchinson Cancer Center)
Dr. Lei Deng is an assistant professor within the Thoracic, Head & Neck medical oncology group, at University of Washington and Fred Hutch Cancer Center. He is interested in clinical and translational thoracic cancer research focusing on novel biomarkers and therapeutics, particularly KRAS-mutated lung cancer. He is also interested in optimizing systemic therapy for patients undergoing curative surgery and definitive radiotherapy. Dr. Deng co-leads the early-career working group at IASLC's Career Development Committee since 2025.
Disclosure
Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Travel Ineligible company: MJH Life Sciences Relationship end date: 06/01/2023 Attribution: Self Type of financial relationship: Other Ineligible company: MJH Life Sciences Relationship end date: 06/08/2022 Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Bristol Meyer Squibb Relationship end date: 03/01/2024 Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Regeneron Relationship end date: 03/06/2024 Attribution: Self Type of financial relationship: Travel Ineligible company: Merck Relationship end date: 04/26/2024 Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Bristol Meyer Squibb Relationship end date: 11/06/2024 Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: BridgeBio Oncology Therapeutics Relationship end date: 03/01/2025
- Medical Oncologists
- Surgeons
- Radiation Oncologists
- Pathologists
- Oncology Fellows
- Oncology Nurses
- Nurse Practitioners
- Physician Assistants
- Pharmacists
Target Audience
- Apply biomarker testing to guide NSCLC treatment choices.
- Select appropriate targeted or immunotherapy based on clinical scenarios.
- Recognize and manage the toxicities of modern lung cancer treatments.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: